BRKR Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of -43.84%. Bruker Corp.'s return on equity of -1.2% beat Avantor, Inc.'s return on equity of -1.4%.

Bruker Corp. has a consensus price target of $51.79, signalling upside risk potential of 9.93%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 16.24%. Given that Avantor, Inc. has higher upside potential than Bruker Corp., analysts believe Avantor, Inc. is more attractive than Bruker Corp..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.414%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.43%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Bruker Corp.'s net income of -$58.5M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 2.08x versus 1.19x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Azenta, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of 32.45%. Bruker Corp.'s return on equity of -1.2% beat Azenta, Inc.'s return on equity of 1.44%.

Bruker Corp. has a consensus price target of $51.79, signalling upside risk potential of 9.93%. On the other hand Azenta, Inc. has an analysts' consensus of $40.17 which suggests that it could grow by 20.77%. Given that Azenta, Inc. has higher upside potential than Bruker Corp., analysts believe Azenta, Inc. is more attractive than Bruker Corp..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.316, suggesting its more volatile than the S&P 500 by 31.601%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.43%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Azenta, Inc. quarterly revenues of $159.2M. Bruker Corp.'s net income of -$58.5M is lower than Azenta, Inc.'s net income of $51.7M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 2.08x versus 2.56x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of -5.98%. Bruker Corp.'s return on equity of -1.2% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Bruker Corp. has a consensus price target of $51.79, signalling upside risk potential of 9.93%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 199.04%. Given that Harvard Bioscience, Inc. has higher upside potential than Bruker Corp., analysts believe Harvard Bioscience, Inc. is more attractive than Bruker Corp..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.526, suggesting its more volatile than the S&P 500 by 52.562%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.43%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bruker Corp.'s net income of -$58.5M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 2.08x versus 0.34x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of 6.76%. Bruker Corp.'s return on equity of -1.2% beat Revvity, Inc.'s return on equity of 3.05%.

Bruker Corp. has a consensus price target of $51.79, signalling upside risk potential of 9.93%. On the other hand Revvity, Inc. has an analysts' consensus of $114.38 which suggests that it could grow by 18.22%. Given that Revvity, Inc. has higher upside potential than Bruker Corp., analysts believe Revvity, Inc. is more attractive than Bruker Corp..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.054, suggesting its more volatile than the S&P 500 by 5.36%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.43%. Revvity, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.07 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Revvity, Inc. pays out 11.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Revvity, Inc. quarterly revenues of $698.9M. Bruker Corp.'s net income of -$58.5M is lower than Revvity, Inc.'s net income of $47.2M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Revvity, Inc.'s PE ratio is 48.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 2.08x versus 4.08x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.